SEC Tracker
Get the app

uniQure QURE

Matthew C Kapusta (Director) plans to sell 226,316 QURE shares, about $9.4M

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: Sep 24, 2025
  2. Broker: CITIGROUP GLOBAL MARKETS
  3. Shares acquired by: STOCK OPTION EXERCISE AND SALE PURSUANT TO 10B51 PLAN
  4. 10b5-1 plan adopted: Jan 28, 2025

All of Matthew C Kapusta's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 51,316 shares at $39.59 on Sep 24, 2025 · Form 4
  • Sold 60,000 shares at $40.04 on Sep 24, 2025 · Form 4
  • Sold 49,978 shares at $40.68 on Sep 24, 2025 · Form 4
  • Sold 5,022 shares at $41.69 on Sep 24, 2025 · Form 4
  • Sold 60,000 shares at $45.1 on Sep 24, 2025 · Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when uniQure files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Phibro Animal Health PAHC public float $764M, Dec 31, 2025
  2. Pacira BioSciences PCRX public float $758M, Jun 30, 2025
  3. Cogent Biosciences COGT public float $773M, Jun 30, 2025
  4. Syndax Pharmaceuticals SNDX public float $799M, Jun 30, 2025
  5. Immunome IMNM public float $729M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.